Regulation of the proliferation of colon cancer cells by compounds that affect glycolysis, including 3-bromopyruvate, 2-deoxyglucose and biguanides

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 401-408

  Lea, Michael A ^a   Qureshi, Mehreen S ^a   Buxhoeveden, Michael ^a   Gengel, Nicolette ^a   Kleinschmit, Jessica ^a   Desbordes, Charles ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

2 deoxyglucose; 3 bromopyruvate; Colon cancer; Metformin; Phenformin

Indexed keywords

ALKALINE PHOSPHATASE; BIGUANIDE; BROMOPYRUVIC ACID; DEOXYGLUCOSE; GLUCOSE; METFORMIN; PHENFORMIN; PROTEIN P53; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; GLUCOSE METABOLISM; GLYCOLYSIS; GROWTH RATE; HUMAN; HUMAN CELL; INCUBATION TIME; PH; PRIORITY JOURNAL; WILD TYPE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIGUANIDES; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DEOXYGLUCOSE; GLYCOLYSIS; HT29 CELLS; HUMANS; PYRUVATES;

EID: 84875894405     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lea MA, Chacko J, Bolikal S, Hong JY, Chung R, Ortega A and desBordes C: Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin. Anticancer Res 31: 421-426, 2011.
2. Ganapathy-Kanniappan S, Vali M, Kunjithapathan R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R and Geschwind JF: 3-Bromopyruvate: A new targeted antiglycolytic agent and a promise for cancer therapy. Current Pharm Biotechnol 11: 510-517, 2010.
3. Pedersen PL: 3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective 'small molecule' anticancer agent taken from labside to bedside: Introduction to a special issue. J. Bioenerg Biomembr 44: 1-6, 2012.
4. Shoshan MC: 3-Bromopyruvate: Targets and outcomes. J Bioenerg Biomembr 44: 7-15, 2012.
5. Cardaci S, Desideri E and Ciriolo MR: Targeting aerobic glycolysis: 3-bromopyurvate as a promising anticancer drug. J Bioenerg Biomembr 44: 17-29, 2012.
6. Bunz F, Hwang PM, Torrance C, Waldman Y Zhang Y Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998.
7. Vichai V and Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112-1116, 2006
8. Lea MA, Ibeh C, Shah N and Moyer MP: Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase. Anticancer Res 27: 741-748, 2007.
9. Warburg O, Posener K and Negelein E: Ueber den Stoffwechsel der Tumoren. Biochem Z 152: 319-344, 1924.
10. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
11. Ko YH, Pedersen PL and Geschwind JF: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: Characterization and targeting hexokinase. Cancer Lett 173: 83-91, 2001.
12. Dell'Antone P: Targets of 3-bromopyruvate, a new, energydepleting, anticancer agent. Med Chem 5: 491-496, 2009.
13. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel, Giogetti-Peraldi, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti J-F and Bost F: Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475, 2010.
14. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Cheng KW, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani, J, Lee JS, Hong WK and Mills GB: Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 10: 2350-2362, 2011.
15. Ganapathy-Kanniappan S, Geschwind JFH, Kunjithapathan R, Buijs M, Syed LH, Rao PP, Ota S and Vali M: The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. Assay Drug Dev Technol 8: 258262, 2010.
16. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B and Pinedo HM: Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27: 897-900, 1991.
17. Fung KYC, Cosgrove L, Lockett T, Head R and Topping DL: A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate. Br J Nutr 108: 820-831, 2012.
18. Levine AJ and Puzio-Kuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340-1344, 2010.
19. Cheong H, Lu C, Lindsten T and Thompson CB: Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol 30: 671-678, 2012.